Physicians' Academy for Cardiovascular Education

The current role of TZD’s in diabetes & CV risk: A critical appraisal of pioglitazone

Slides (presentation) - Mar. 14, 2012

The current role of TZD’s in diabetes & CV risk:
A critical appraisal of pioglitazone


Slides prepared and presented by

Prof. John Betteridge, MD
University College London
London, United Kingdom

Cardio Diabetes Master Class: Asian chapter, March 2012

View slides: click to enlarge

The current role of TZD’s in diabetes & CV risk
Use of Pioglitazone
TZDs are activators of PPAR gamma?
Patho-physiology of Type 2 diabetes
Pioglitazone + existing therapy
Time to Primary Composite Endpoint*
PROactive Total Events
Time to : Death, MI ( excluding silent ) or Stroke
Time to Fatal/Non-fatal MI
Time to Fatal or Non-Fatal Stroke
CHICAGO:Glycaemic Control Change in HbA1c
CHICAGO: Treatment effect on posterior wall mean CIMT
PERISCOPE IVUS Trial Primary Endpoint
PERISCOPE: Comparison to Other Trials
Benefits of Pioglitazone: Lipid Metabolism
PROactive Metabolic Effects of Pioglitazone
Burden in T2DM: Events in Controlled Clinical Studies
Bladder Cancer: Clinical Trials
Bladder Cancer: Epidemiological Studies
KPNC 3rd Interim Analysis
CNAMTS Overall Results
Overall Malignancies
Bladder Cancer Conclusions
Slide 28
European Medicines Agency
European Medicines Agency

Share this page with your colleagues and friends: